Compare CODI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODI | ADCT |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.8M | 484.4M |
| IPO Year | N/A | 2019 |
| Metric | CODI | ADCT |
|---|---|---|
| Price | $6.33 | $4.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $8.00 | $7.50 |
| AVG Volume (30 Days) | ★ 1.2M | 812.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | ★ 44.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,837,000.00 |
| Revenue This Year | $0.93 | $14.96 |
| Revenue Next Year | $6.35 | $1.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.84 |
| 52 Week Low | $4.58 | $1.05 |
| 52 Week High | $20.07 | $4.80 |
| Indicator | CODI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 51.41 |
| Support Level | $6.15 | $3.25 |
| Resistance Level | $7.33 | $4.71 |
| Average True Range (ATR) | 0.56 | 0.25 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 0.24 | 29.76 |
Compass Diversified Holdings is a diversified business conglomerate based in the United States having two groups: branded consumer business and industrial business. Branded consumer businesses are characterized as those businesses that capitalize on a valuable brand name in their respective market sector. It includes 5.11, Ergobaby, Liberty Safe, and Velocity Outdoor. Industrial businesses are characterized as those businesses that focus on manufacturing and selling particular products and industrial services within a specific market sector. The company has operations in the United States, Canada, Europe, Asia Pacific, and other International areas.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).